Stanley T. Lewis

Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

Brinda Emu, Jeffrey Fessel, Shannon Schrader et al. · New England Journal of Medicine · 2018 · 223 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected Adults

Jeffrey M. Jacobson, Daniel R. Kuritzkes, Eliot Godofsky et al. · Antimicrobial Agents and Chemotherapy · 2008 · 160 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 145 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Catherine Orrell, Debbie Hagins, Elena Belonosova et al. · The Lancet HIV · 2017 · 118 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab

Jonathan Toma, Steven P. Weinheimer, Eric Stawiski et al. · Journal of Virology · 2011 · 70 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17